Product Description
Ibuprofen is a medication used to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis. It is in the non-steroidal anti-inflammatory drug (NSAID) class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK542299/)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, China, Denmark, Ireland, Italy, Jordan, Mexico, Pakistan, Qatar, Spain, Switzerland, United States, Unknown Location
Active Clinical Trial Count: 36
Highest Development Phases
Phase 3: Chronic Pain|Common Cold|Conduct Disorder|Depressive Disorder|Ductus Arteriosus, Patent|Influenza, Human|Labor Pain|Malnutrition|Neuropathic Pain|Osteoarthritis|Pain Unspecified|Pain, Postoperative|Pelvic Pain|Respiratory Tract Infections|Tooth, Impacted
Phase 2: Acute Pain|Arthritis|Cellulite|Low Back Pain|Mastoiditis|Morphine Dependence|Osteoarthritis, Knee|Other|Otitis|Pregnancy Outcomes|Transitional Cell Carcinoma
Phase 1: Headache|Healthy Volunteers|Insomnia|Migraine Disorders|Neuralgia|Prostate Cancer|Toothache
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-510792-38-00 | P3 |
Unknown Status |
Pain Unspecified |
2029-03-01 |
|
| PRPNSAIDsKOA | P2 |
Recruiting |
Chronic Pain|Osteoarthritis, Knee |
2026-12-31 |
|
| 2023-503209-13-00 | P2 |
Unknown Status |
Ductus Arteriosus, Patent |
2026-03-30 |
|
| OXIFEN | P3 |
Recruiting |
Pain, Postoperative|Labor Pain |
2025-05-28 |
95% |
| OXIFEN | P3 |
Recruiting |
Pain, Postoperative|Labor Pain |
2025-05-28 |
95% |